Correlation Between Inozyme Pharma and Apogee Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Apogee Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Apogee Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inozyme Pharma and Apogee Therapeutics, Common, you can compare the effects of market volatilities on Inozyme Pharma and Apogee Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Apogee Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Apogee Therapeutics,.

Diversification Opportunities for Inozyme Pharma and Apogee Therapeutics,

0.68

Correlation Coefficient

Inozyme Pharma  Apogee Therapeutics,

Poor diversification

The 3 months correlation between Inozyme and Apogee is 0.68. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Apogee Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apogee Therapeutics, and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Apogee Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apogee Therapeutics, has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Apogee Therapeutics, go up and down completely randomly.

Pair Corralation between Inozyme Pharma and Apogee Therapeutics,

Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the Apogee Therapeutics,. But the stock apears to be less risky and, when comparing its historical volatility, Inozyme Pharma is 1.05 times less risky than Apogee Therapeutics,. The stock trades about -0.26 of its potential returns per unit of risk. The Apogee Therapeutics, Common is currently generating about -0.04 of returns per unit of risk over similar time horizon. If you would invest  5,150  in Apogee Therapeutics, Common on September 15, 2024 and sell it today you would lose (700.00) from holding Apogee Therapeutics, Common or give up 13.59% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Inozyme Pharma  vs.  Apogee Therapeutics, Common

Inozyme Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Apogee Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Apogee Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest inconsistent performance, the Stock's technical and fundamental indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

Pair Trading with Inozyme Pharma and Apogee Therapeutics,

The main advantage of trading using opposite Inozyme Pharma and Apogee Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Apogee Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apogee Therapeutics, will offset losses from the drop in Apogee Therapeutics,'s long position.

The idea behind Inozyme Pharma and Apogee Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.